“Advancements in Long-Acting Formulations and Targeted Delivery Systems”
- A significant and accelerating trend in the global veterinary corticosteroids market is the shift toward long-acting injectable formulations and species-specific delivery systems that offer improved treatment compliance and reduced dosing frequency for both companion and livestock animals. These innovations are enhancing clinical outcomes while minimizing adverse effects and stress on animals
- For instance, sustained-release corticosteroids such as methylprednisolone acetate are gaining popularity in treating chronic inflammatory conditions in horses and dogs, offering relief for extended periods with a single dose. In livestock, such formulations are used to manage stress-related inflammation during transport or disease outbreaks with minimal handling
- Targeted drug delivery—such as intra-articular injections for canine osteoarthritis or topical corticosteroid sprays for dermatological conditions—is becoming more prevalent, allowing for localized treatment and reduced systemic exposure
- These technologies are especially beneficial in multi-animal settings and for chronic conditions where daily dosing may be impractical. Furthermore, advancements in transdermal gels and medicated feed supplements are expanding the range of administration options available to veterinarians
- The demand for these advanced corticosteroid therapies is growing rapidly across both clinical veterinary practices and large-scale animal farms, as they offer improved outcomes with reduced treatment burden and cost. Consequently, key players such as Zoetis, Boehringer Ingelheim, and Elanco are investing in R&D for novel corticosteroid delivery methods tailored to animal health needs
- This trend toward more targeted, effective, and species-adapted corticosteroid therapies is fundamentally reshaping expectations around veterinary treatment protocols and is expected to drive strong growth in the coming years
